BioSpace News Archive

Business

Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results

Evoke will hold a conference call on Tuesday, November 14, 2017 at 4:30 pm ET to discuss the results.

November 7, 2017

·

1 min read

Business

Personalis Wins New Contract to Sequence >34,000 Whole Human Genomes for the VA’s Million Veteran Program

The company has also developed sophisticated data systems for tracking such large numbers of human genetic samples, for efficiently processing and managing the flow of many petabytes of genetic data, and for maintaining auditable quality at large scale.

November 7, 2017

·

3 min read

Drug Development

Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution

Under the proposed transaction, a new entity established by the third party would provide both the necessary capital to fund and the clinical expertise to execute an additional Phase 3 pivotal trial for SB204.

November 7, 2017

·

4 min read

Drug Development

Calithera Biosciences’ Initial Results From Phase II Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting

CB-839 is an orally bioavailable glutaminase inhibitor currently in Phase 2 trials, and Opdivo® is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

November 7, 2017

·

7 min read

Business

AlloSource Announces Bob Lay as COO

With over 20 years of experience in both finance and operations, Bob has a broad-based understanding of how each department within an organization impacts another.

November 7, 2017

·

2 min read

Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017

The company intends to host a conference call the same day at 5:00 p.m. ET to discuss the financial results.

November 7, 2017

·

1 min read

Drug Development

DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials

The study was designed to compare the profile of DM199 to that of the approved urinary KLK1 product (trade name Kailikang) on the market in Asia for acute ischemic stroke.

November 7, 2017

·

5 min read

Business

Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress

In the three months ended Sept. 30, 2017 and 2016, we recognized $1.9 million and $1.3 million, respectively, of revenue associated with our Pfizer collaboration.

November 7, 2017

·

11 min read

Business

Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B

Spark Therapeutics to receive up to an additional $25 million per terms of amendment.

November 7, 2017

·

8 min read

Business

Repligen Extends Long Term Supply Agreement With Purolite for Protein A Ligands

Pursuant to the agreement, Repligen will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025.

November 7, 2017

·

4 min read